Sampo plc
Sampo plc’s share buybacks 2 January 2026
Sampo plc’s share buybacks 2 January 2026
Sampo plc, stock exchange release, 5 January 2026 at 8:30 am EET
Sampo plc’s share buybacks 2 January 2026
On 2 January 2026, Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:
| Sampo plc’s share buybacks | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares* | Market (MIC Code) |
| 6,077 | 10.34 | AQEU | |
| 113,197 | 10.32 | CEUX | |
| 31,491 | 10.31 | TQEX | |
| 127,047 | 10.32 | XHEL | |
| TOTAL | 277,812 | 10.32 |
* rounded to two decimals
On 5 November 2025, Sampo announced a share buyback programme of up to a maximum of EUR 150 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 6 November 2025, is based on the authorisation granted by Sampo's Annual General Meeting on 23 April 2025.
After the disclosed transactions, the company owns in total 9,223,315 Sampo A shares representing 0.35 per cent of the total number of shares in Sampo plc.
Details of each transaction are included as an appendix of this announcement.
On behalf of Sampo plc,
Morgan Stanley
For further information, please contact:
Sami Taipalus
Head of Investor Relations
tel. +358 10 516 0030
Distribution:
Nasdaq Helsinki
Nasdaq Stockholm
Nasdaq Copenhagen
London Stock Exchange
FIN-FSA
The principal media
www.sampo.com
Attachment
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alvotech6.1.2026 21:00:00 CET | Press release
Transactions of Managers and Closely Associated Persons
Alvotech6.1.2026 21:00:00 CET | Press release
Transactions of Managers and Closely Associated Persons
Zymeworks Inc.6.1.2026 19:34:22 CET | Press release
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
KBC Groep6.1.2026 18:45:00 CET | Press release
KBC Group: KBC Securities and Van Lanschot Kempen Investment Banking announce joint venture in equities
Sequana Medical NV6.1.2026 18:00:00 CET | Press release
Transparency Notification from Shareholders
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom